Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis

Heart Lung and Circulation

Volumn 25, Issue 1, 2016, Pages 46-52

  Badiani, Brigitta ^a   Messori, Andrea ^a  

^a ESTAV Toscana Centro   (Italy)

Author keywords

Endothelin receptor antagonists; Meta analysis; Phosphodiesterase type 5 inhibitors; Prostacyclin; Prostanoids; Pulmonary arterial hypertension; Soluble guanylate cyclase stimulators

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; GUANYLATE CYCLASE ACTIVATOR; MACITENTAN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN DERIVATIVE; PROSTANOID; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; TREPROSTINIL; VARDENAFIL; CELL RECEPTOR; GUANYLATE CYCLASE; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN; SOLUBLE GUANYLYL CYCLASE;

ARTICLE; BAYES THEOREM; CLINICAL EFFECTIVENESS; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; AGONISTS; COMPARATIVE STUDY; FEMALE; HYPERTENSION, PULMONARY; MALE;

ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, EPOPROSTENOL;

EID: 84938150527     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2015.05.020     Document Type: Article

References (32)

1. Montani D., Chaumais M.C., Guignabert C., Günther S., Girerd B., Jaïs X., et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 2014, 141:172-191.
2. Benza R.L., Miller D.P., Barst R.J., Badesch D.B., Frost A.E., McGoon M.D. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest 2012, 142:448-456.
3. O'Callaghan D.S., Savale L., Montani D., Jaïs X., Sitbon O., Simonneau G., Humbert M. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011, 8:526-538.
4. Galiè N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC; and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart 2009, 30:2493-2537.
5. Zheng Y.G., Ma H., Hu E.C., Liu G., Chen G., Xiong C.M. Oral targeted therapies in the treatment of pulmonary arterial hypertension: A meta-analysis of clinical trials. Pulm Pharmacol Ther 2014, 29:241-249.
6. Montedori A., Bonacini M.I., Casazza G., Luchetta M.L., Duca P., Cozzolino F., Abraha I. Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study. Trials 2011, 10.1186/1745-6215-12-58.
7. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313-2324.
8. Jansen J.P., Fleurence R., Devine B., Itzler R., Barrett A., Hawkins N., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011, 14:417-428.
9. Hoaglin D.C., Hawkins N., Jansen J.P., Scott D.A., Itzler R., Cappelleri J.C., et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011, 14:429-437.
10. Greco T., Landoni G., Biondi-Zoccai G., D'Ascenzo F., Zangrillo A. A Bayesian network meta-analysis for binary outcome: how to do it. Stat Methods Med Res 2013, 10.1177/0962280213500185.
11. NICE Clinical Guidelines, No. 92.2010; National Clinical Guideline Centre - Acute and Chronic Conditions (UK). London: Royal College of Physicians (UK) Available at 10 January 2015. http://www.ncbi.nlm.nih.gov/books/NBK116530/.
12. Thorlund K., Thabane L., Mills E.J. Modelling heterogeneity variances in multiple treatment comparison meta-analysis-are informative priors the better solution?. BMC Med Res Methodol. 2013, 13(Jan 11):2.
13. Barst R.J., McGoon M., McLaughlin V., Tapson V., Rich S., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003, 41:2119-2125. Beraprost Study Group.
14. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
15. Galiè N., Humbert M., Vachiéry J.L., Vizza C.D., Kneussl M., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002, 39:1496-1502. Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group.
16. Galiè N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group.
17. Galiè N., Beghetti M., Gatzoulis M.A., Granton J., Berger R.M., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006, 114:48-54. Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators.
18. Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group, Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010-3019.
19. Galiè N., Rubin Lj, Hoeper M., Jansa P., Al-Hiti H., Meyer G., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008, 371:2093-2100.
20. Galiè N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903. Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group.
21. Ghofrani H.A., Galiè N., Grimminger F., Grünig E., Humbert M., Jing Z.C., et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369:330-340.
22. Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group, Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011; 183:1723-1729.
23. Jing Z.C., Parikh K., Pulido T., Jerjes-Sanchez C., White R.J., Allen R., et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013, 127:624-633.
24. SERAPHIN Investigators, Pulido T., Adzerikho I., Channick R.N., Delcroix M., Galiè N., Ghofrani H.A., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013, 369:809-818.
25. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
26. Tapson V.F., Torres F., Kermeen F., Keogh A.M., Allen R.P., Frantz R.P., et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012, 142:1383-1390.
27. Tapson V.F., Jing Z.C., Xu K.F., Pan L., Feldman J., Kiely D.G., et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013, 144:952-958.
28. Actelion. Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON TrialClinicalTrials.gov Available at: access 15 January 2015. https://clinicaltrials.gov/ct2/show/NCT01106014.
29. Actelion. Selexipag meets primary endpoint in pivotal phase III GRIPHON outcome study in patients with pulmonary arterial hypertension. access 15 January 2015. http://www1.actelion.com/en/our-company/news-and-events.page?newsId=1793163.
30. Galiè N., Manes A., Negro L., Palazzini M., Bacchi-Reggiani M.L., Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009, 30(4 (Feb)):394-403.
31. Macchia A., Marchioli R., Marfisi R., Scarano M., Levantesi G., Tavazzi L., Tognoni G. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007, 153(6 (Jun)):1037-1047.
32. Altman D.G., Bland J.M. How to obtain the confidence interval from a P value. BMJ 2011, 343(Aug 8):d2090.